BIOLOGICAL · Unmapped registry intervention
Cixutumumab
Find medicine records ·
Find other trials using this name
Clinical trial
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
NCT01026623
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
OTHER · Unmapped registry intervention
Diagnostic Laboratory Biomarker Analysis
Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Temsirolimus
Normalized identity: temsirolimusView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedCixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
CixutumumabBIOLOGICAL
TemsirolimusDRUG · verified · RxNorm: temsirolimus
Sponsors & collaborators
National Cancer Institute (NCI)lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01026623 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.